PMC:7283670 / 67889-68147 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T381","span":{"begin":14,"end":22},"obj":"Disease"},{"id":"T382","span":{"begin":67,"end":75},"obj":"Disease"}],"attributes":[{"id":"A381","pred":"mondo_id","subj":"T381","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A382","pred":"mondo_id","subj":"T382","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Fingolimod in COVID‐19 Biological: UC‐MSCs, other: placebo China/COVID‐19 30, all, 18–80 Treatment Experimental: treatment group: each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T601","span":{"begin":86,"end":88},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"}],"text":"Fingolimod in COVID‐19 Biological: UC‐MSCs, other: placebo China/COVID‐19 30, all, 18–80 Treatment Experimental: treatment group: each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T222","span":{"begin":128,"end":133},"obj":"Chemical"},{"id":"T223","span":{"begin":155,"end":165},"obj":"Chemical"},{"id":"T224","span":{"begin":176,"end":181},"obj":"Chemical"},{"id":"T225","span":{"begin":202,"end":212},"obj":"Chemical"}],"attributes":[{"id":"A222","pred":"chebi_id","subj":"T222","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A223","pred":"chebi_id","subj":"T223","obj":"http://purl.obolibrary.org/obo/CHEBI_63115"},{"id":"A224","pred":"chebi_id","subj":"T224","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A225","pred":"chebi_id","subj":"T225","obj":"http://purl.obolibrary.org/obo/CHEBI_63115"}],"text":"Fingolimod in COVID‐19 Biological: UC‐MSCs, other: placebo China/COVID‐19 30, all, 18–80 Treatment Experimental: treatment group: each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days"}

{"project":"LitCovid-sentences","denotations":[{"id":"T660","span":{"begin":0,"end":258},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Fingolimod in COVID‐19 Biological: UC‐MSCs, other: placebo China/COVID‐19 30, all, 18–80 Treatment Experimental: treatment group: each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1905","span":{"begin":140,"end":147},"obj":"Species"}],"attributes":[{"id":"A1905","pred":"tao:has_database_id","subj":"1905","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Fingolimod in COVID‐19 Biological: UC‐MSCs, other: placebo China/COVID‐19 30, all, 18–80 Treatment Experimental: treatment group: each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days"}